Endoscopic submucosal dissection for gastric neuroendocrine neoplasms: A multicenter retrospective study

This is the authors' abstract. We don't add key points for this paper.

Endoscopic submucosal dissection (ESD) has been reported as a feasible and effective treatment for Gastric Neuroendocrine Tumors (G-NETs). However, most of the experience comes from retrospective tertiary centers in Eastern Asia. Data coming from western centers are lacking. This is a retrospective study, including patients who underwent endoscopic resection of G-NETs by ESD between 2010 and 2020 in Western Centers. Important clinical variables such as demographic, size, type, presence of lymphovascular invasion or distant metastasis, completeness of the endoscopic resection, recurrence, and procedure-related complications were recorded. Seventy-three ESD procedures on G-NETs from 69 patients from 11 centers were included. Median G-NETs size on endoscopy was 12 mm (IQR 10-15). Case mix accounted for 83.6% type 1, 15.1% type 3, and 1.4% type 2. En-bloc resection was possible in 69 procedure 94.5%, R0 resection rate stood at 79.5%. Five patients (7.2%) were referred for additional surgical intervention. One case of perforation was reported (1.4%), treated endoscopically. Three patients (4.4%) had evidence of recurrence during follow-up. ESD is an effective and safe treatment for G-NETs in western centers.